Actively Recruiting
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL
Led by Chongqing Precision Biotech Co., Ltd · Updated on 2025-02-25
40
Participants Needed
1
Research Sites
329 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted prime CAR-T cells therapy for patients with relapsed/refractory B -ALL
CONDITIONS
Official Title
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed written informed consent
- Diagnosed with relapsed or refractory B-ALL meeting at least one of: failed standard chemotherapy, relapse after remission with high-risk/refractory status, or relapse after hematopoietic stem cell transplantation
- For Ph+ ALL patients: received standard induction chemotherapy and either did not achieve remission after TKI treatment or relapsed after remission (excluding TKI-resistant patients)
- Evidence of CD19 or CD22 cell membrane expression
- All genders aged 2 to 75 years
- Expected survival time greater than 3 months
- Karnofsky Performance Status (KPS) over 60
- No serious mental disorders
- Left ventricular ejection fraction 50% or higher
- Adequate liver function: ALT/AST no more than 3 times upper limit of normal (ULN), bilirubin no more than 2 times ULN
- Adequate kidney function: creatinine clearance no more than 2 times ULN
- Adequate lung function: oxygen saturation 92% or higher indoors
- Eligible for single or venous blood collection with no contraindications
- Ability and willingness to follow study visits and protocol requirements
You will not qualify if you...
- History of other malignancies
- Presence of uncontrolled active infection
- Disorders requiring glucocorticoid treatment
- Active or chronic graft-versus-host disease (GVHD)
- Treatment with T cell inhibitors
- Pregnant or breastfeeding women
- Any condition deemed unsuitable by investigators, such as HIV, HCV infection, or intravenous drug addiction, that may affect study participation or data analysis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
920th Hospital of Joint Logistics Support Force
Kunming, Yunnan, China
Actively Recruiting
Research Team
Z
Zhi Yang, PhD
CONTACT
S
Sanbin Wang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here